Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
|Articles|December 14, 2017
Controversies in Treating Early HR-Positive Breast Cancer
Author(s)Vered Stearns, MD
This video reviews controversies in the treatment of early-stage hormone receptor (HR)-positive breast cancer.
Advertisement
In this video, Vered Stearns, MD, of Johns Hopkins School of Medicine in Baltimore, Maryland, reviews controversies in the treatment of early-stage hormone receptor (HR)-positive breast cancer.
Stearns gave a presentation on this topic at the 2017 San Antonio Breast Cancer Symposium (SABCS), held December 5–9 in San Antonio, Texas.
Advertisement
Related to this article
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
Tyler J. Wilhite, MD, discussed coordinating with rheumatology, orthopedic surgery, and primary care when treating patients with osteoarthritis with low-dose radiation therapy.
Tyler J. Wilhite, MD, discussed scaling low-dose radiation therapy for osteoarthritis from 1 patient to nearly 20 centers and the referral work behind it.
Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.
Parul N. Barry, MD, FACRO, discussed extending advanced radiation services to satellite sites and offered guidance for early-career physicians building new programs.
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
Setting Up an HDR Brachytherapy Program Amid a National Decline
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
5